Celularity Inc Stock Price, News & Analysis

Celularity (NASDAQ:CELU), a regenerative and cellular medicine company, announced receiving a notice from Nasdaq on August 21, 2025, regarding its failure to file the Q2 2025 Form 10-Q. This marks the company's second delayed quarterly filing, following the Q1 2025 Form 10-Q.

The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1), though this notice does not immediately affect CELU's listing status. Nasdaq has given Celularity until September 5, 2025 to update its compliance plan, with a final deadline of November 17, 2025 to file all delinquent reports.

Celularity (NASDAQ:CELU) has completed a significant balance sheet restructuring, successfully retiring all $41.6 million in senior secured debt, including $32.0 million in principal and $9.6 million in unpaid interest. The company executed this through an Asset Purchase Agreement with Celeniv Pte. Ltd., selling its intellectual property assets while maintaining exclusive licensing rights for 5 years with renewal options.

The transaction included a $33.8 million consideration used to retire debt from RWI and a Promissory Note from Mr. Lim. Additionally, Celularity completed an internal restructuring, creating six wholly-owned subsidiaries for its commercial units: biomaterials, longevity cell therapy, biobanking, contract manufacturing, discovery & development, and asset holding.

Celularity (Nasdaq: CELU) has formed a strategic partnership with Fountain Life to provide stem cell therapy products in Florida, leveraging a new state law effective July 1, 2025. The legislation allows qualified physicians to administer stem cell treatments for orthopedic conditions, wound healing, and pain management without FDA IND approval.

Fountain Life operates four longevity centers, including two in Florida (Naples and Lake Nona-Orlando), with Miami opening soon. Celularity will supply clinical-grade, placental-derived stem cells from its FDA-registered facility in New Jersey, offering immediate availability for physician-directed use under the new regulatory framework.

Celularity (Nasdaq: CELU), a regenerative and cellular medicine company, welcomes a new Florida law effective July 1, 2025, that authorizes physicians to provide investigational stem cell therapies for orthopedics, wound care, and pain management. The legislation permits the use of non-FDA approved stem cell treatments under strict safety and ethical guidelines.

The law requires stem cells to be sourced from FDA-registered and certified/accredited facilities that comply with Good Manufacturing Practices. Physicians must obtain patient informed consent before administering treatments. Celularity, operating an FDA-registered facility with extensive stem cell inventory, is positioned to supply ethically sourced placenta-derived stem cells for these authorized therapies.

The company, through its predecessor Anthrogenesis Corporation, pioneered the discovery of placental stem cell recovery methods in 2001, which was acknowledged by President George W. Bush. The Florida Medical Association was actively involved in crafting the legislation to balance public protection and physician regulation.

Celularity announced the immediate termination of CFO David Beers, with the termination being 'without cause' and unrelated to financial or operating results. Joseph DosSantos, current Senior Vice President Finance, has been appointed as interim CFO effective June 10, 2025, while maintaining his existing role without additional compensation. The company has retained CFO Squad, a financial advisory firm, to provide SEC reporting support and consulting services during the transition. CFO Squad will work under John R. Haines, Celularity's Senior Executive Vice President and Chief Administrative Officer, to optimize financial processes and systems.

Celularity (NASDAQ: CELU) has published research in Regenerative Engineering and Translational Medicine demonstrating the effectiveness of their proprietary tri-layer decellularized, dehydrated human amniotic membrane (DDHAM-3L) technology. The study, conducted with North Carolina State University, shows DDHAM-3L's potential as a carrier for induced pluripotent stem cell (iPSC)-derived limbal stem cells in treating limbal stem cell deficiency and ocular surface disorders. The 7-day in vitro study revealed that iPSC-LSCs seeded on DDHAM-3L formed confluent cell sheets, showed epithelial morphology, and demonstrated higher proliferation rates compared to controls. The technology shows promise for delivering patient-specific stem cells for vision restoration and has potential applications beyond ophthalmology.

Celularity (NASDAQ: CELU) has received a notice from Nasdaq on May 28, 2025, regarding its failure to file the Q1 2025 Form 10-Q on time. This non-compliance with Listing Rule 5250(c)(1) gives the company 60 days to submit a compliance plan to Nasdaq. If accepted, Nasdaq may extend the compliance deadline to November 17, 2025. The notice does not immediately affect CELU's listing or trading status. The company states it is working to complete the delayed quarterly report and expects to maintain SEC reporting compliance thereafter.

Celularity (NASDAQ: CELU) reported strong financial results for FY2024, with net revenues reaching $54.2 million, marking a significant 138.1% increase from the previous year. The growth was primarily driven by a 168.7% increase in wound care product sales, contributing $22.2 million to the revenue increase. Operating expenses decreased by 57% to $92.6 million, mainly due to the absence of goodwill and IPR&D impairments. The company's loss from operations improved substantially, decreasing by 80.1% to $38.4 million. The Biovance® product line showed particularly strong performance, and the company received recommendation letters from the FDA Tissue Reference Group for additions to their placental-derived biomaterial products portfolio.

Celularity (CELU) faces potential delisting from Nasdaq due to two separate issues. First, the company failed to pay required fees of $70,000 under Listing Rule 5250(f), which was subsequently paid in full on April 25, 2025. Second, Nasdaq notified the company on April 16, 2024, about its delinquency in filing the Form 10-K for the year ended December 31, 2024, violating Listing Rule 5250(c)(1).

If Celularity doesn't appeal these determinations, trading of its common stock will be suspended on May 1, 2025. The company must address both compliance issues before a Hearings Panel if it appeals. Celularity states it is actively working on filing the 2024 Form 10-K and expects to complete it imminently.